Teva Pharmaceutical Industries Lt.../ US8816242098 /
2024-04-18 10:10:00 PM | Chg. -0.40 | Volume | Bid1:16:28 PM | Ask1:16:28 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
12.78USD | -3.03% | 8.96 mill. Turnover: 94.03 mill. |
12.55Bid Size: 100 | 12.80Ask Size: 500 | 14.33 bill.USD | - | - |
GlobeNewswire
12:10 PM
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...
GlobeNewswire
04-16
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-05
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
GlobeNewswire
02-26
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...
GlobeNewswire
02-24
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...
GlobeNewswire
02-15
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
GlobeNewswire
02-08
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to...
GlobeNewswire
01-31
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic ...
GlobeNewswire
01-29
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Bios...
GlobeNewswire
01-19
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
GlobeNewswire
01-10
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
GlobeNewswire
01-03
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT...
GlobeNewswire
2023-11-29
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Bios...
GlobeNewswire
2023-11-28
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
GlobeNewswire
2023-11-21
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Hos...
GlobeNewswire
2023-11-14
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First...
GlobeNewswire
2023-11-13
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program